TY - JOUR T1 - Mediators of Chronic Obstructive Pulmonary Disease JF - Pharmacological Reviews JO - Pharmacol Rev SP - 515 LP - 548 DO - 10.1124/pr.56.4.2 VL - 56 IS - 4 AU - Peter J. Barnes Y1 - 2004/12/01 UR - http://pharmrev.aspetjournals.org/content/56/4/515.abstract N2 - Chronic obstructive pulmonary disease (COPD) is a major and increasing global health problem that is now a leading cause of death. COPD is associated with a chronic inflammatory response, predominantly in small airways and lung parenchyma, which is characterized by increased numbers of macrophages, neutrophils, and T lymphocytes. The inflammatory mediators involved in COPD have not been clearly defined, in contrast to asthma, but it is now apparent that many lipid mediators, inflammatory peptides, reactive oxygen and nitrogen species, chemokines, cytokines, and growth factors are involved in orchestrating the complex inflammatory process that results in small airway fibrosis and alveolar destruction. Many proteases are also involved in the inflammatory process and are responsible for the destruction of elastin fibers in the lung parenchyma, which is the hallmark of emphysema. The identification of inflammatory mediators and understanding their interactions is important for the development of anti-inflammatory treatments for this important disease. ER -